{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:17:59Z","timestamp":1792534679300,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.pharep.2016.04.002","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T14:29:18Z","timestamp":1462026558000},"page":"748-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile"],"prefix":"10.1007","volume":"68","author":[{"given":"Rafa\u0142 R.","family":"Jaeschke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-7229","authenticated-orcid":false,"given":"Magdalena","family":"Sowa-Ku\u0107ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Pa\u0144czyszyn-Trzewik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Misztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Stycze\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Datka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2016.04.002_bib0375","series-title":"Desk reference to the diagnostic criteria from DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"9","key":"10.1016\/j.pharep.2016.04.002_bib0380","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.4088\/JCP.14com09571","article-title":"Managing antipsychotic medications in schizophrenia: comprehensive assessment and personalized care to improve clinical outcomes and reduce costs","volume":"76","author":"Liperoti","year":"2015","journal-title":"J Clin Psychiatry"},{"issue":"9859","key":"10.1016\/j.pharep.2016.04.002_bib0385","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","article-title":"Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010","volume":"380","author":"Salomon","year":"2012","journal-title":"Lancet"},{"issue":"9904","key":"10.1016\/j.pharep.2016.04.002_bib0390","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"382","author":"Whiteford","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharep.2016.04.002_bib0395","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1017\/S109285291300014X","article-title":"\u201cMeta-guidelines\u201d for the management of patients with schizophrenia","volume":"18","author":"Stahl","year":"2013","journal-title":"CNS Spectr"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/bdi.12025","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013","volume":"15","author":"Yatham","year":"2013","journal-title":"Bipolar Disord"},{"issue":"9","key":"10.1016\/j.pharep.2016.04.002_bib0405","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11634500-000000000-00000","article-title":"Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis","volume":"26","author":"De Hert","year":"2012","journal-title":"CNS Drugs"},{"issue":"9896","key":"10.1016\/j.pharep.2016.04.002_bib0410","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharep.2016.04.002_bib0415","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40263-013-0070-1","article-title":"The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia","volume":"27","author":"Awad","year":"2013","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pharep.2016.04.002_bib0420","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1017\/S0033291714001214","article-title":"The quality of reporting of phase II and III trials for new antipsychotics: a systematic review","volume":"45","author":"Patel","year":"2015","journal-title":"Psychol Med"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0425","doi-asserted-by":"crossref","first-page":"225","DOI":"10.12740\/PP\/39370","article-title":"Guidelines for the use of second-generation long-acting antipsychotics","volume":"49","author":"Jarema","year":"2015","journal-title":"Psychiatr Pol"},{"key":"10.1016\/j.pharep.2016.04.002_bib0430","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12888-014-0351-3","article-title":"A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia","volume":"14","author":"Downing","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.pharep.2016.04.002_bib0435","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5414\/CP202289","article-title":"Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia","volume":"53","author":"Zhang","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2016.04.002_bib0440","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.schres.2013.08.020","article-title":"Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo","volume":"150","author":"Stauffer","year":"2013","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.pharep.2016.04.002_bib0445","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.pharep.2016.04.002_bib0450","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia \u2013 results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2016.04.002_bib0455","series-title":"Users\u2019 guides to the medical literature: a manual for evidence-based clinical practice","first-page":"9","article-title":"The philosophy of evidence-based medicine","author":"Guyatt","year":"2008"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0460","first-page":"109","article-title":"Randomized controlled trials in psychiatry","volume":"46","author":"Jaeschke","year":"2012","journal-title":"Psychiatr Pol"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0465","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2014.5559","article-title":"How to read a systematic review and meta-analysis and apply the results to patient care: users\u2019 guides to the medical literature","volume":"312","author":"Murad","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharep.2016.04.002_bib0470","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0269881113477709","article-title":"Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness","volume":"27","author":"Lochmann van Bennekom","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0475","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0480","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2016.04.002_bib0485","series-title":"LATUDA\u00ae (lurasidone HCl) Tablets","author":"FDA","year":"2010"},{"issue":"10","key":"10.1016\/j.pharep.2016.04.002_bib0490","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12325-012-0052-6","article-title":"Lurasidone in schizophrenia: new information about dosage and place in therapy","volume":"29","author":"Citrome","year":"2012","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.pharep.2016.04.002_bib0495","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0500","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbr.2007.12.006","article-title":"Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets","volume":"195","author":"Terry","year":"2008","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0505","doi-asserted-by":"crossref","first-page":"243","DOI":"10.12740\/PP\/38250","article-title":"Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic \u2013 lurasidone","volume":"49","author":"Bienkowski","year":"2015","journal-title":"Psychiatr Pol"},{"issue":"4","key":"10.1016\/j.pharep.2016.04.002_bib0510","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3371\/CSRP.4.4.5","article-title":"Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic","volume":"4","author":"Citrome","year":"2011","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.pharep.2016.04.002_bib0515","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/NDT.S18059","article-title":"Critical appraisal of lurasidone in the management of schizophrenia","volume":"8","author":"Caccia","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"10.1016\/j.pharep.2016.04.002_bib0520","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.2338","article-title":"Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies","volume":"28","author":"Preskorn","year":"2013","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pharep.2016.04.002_bib0525","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/TCRM.S12701","article-title":"Clinical potential of lurasidone in the management of schizophrenia","volume":"7","author":"Samalin","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.pharep.2016.04.002_bib0530","first-page":"2143","article-title":"Lurasidone for the treatment of bipolar depression: an evidence-based review","volume":"11","author":"Franklin","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0535","first-page":"120","article-title":"A current review of cytochrome P450 interactions of psychotropic drugs","volume":"26","author":"Madhusoodanan","year":"2014","journal-title":"Ann Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2016.04.002_bib0540","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug\u2013drug interaction studies: a comprehensive review","volume":"29","author":"Chiu","year":"2014","journal-title":"Drug Metabol Drug Interact"},{"key":"10.1016\/j.pharep.2016.04.002_bib0545","unstructured":"U.S. National Library of Medicine Toxicology Data Network."},{"issue":"7","key":"10.1016\/j.pharep.2016.04.002_bib0550","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2165\/11631640-000000000-00000","article-title":"Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management","volume":"26","author":"Levine","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharep.2016.04.002_bib0555","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1017\/S1461145713000928","article-title":"Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia","volume":"16","author":"Meltzer","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2016.04.002_bib0560","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2007.06.058","article-title":"Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test","volume":"572","author":"Ishiyama","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0565","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbr.2007.08.012","article-title":"Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats","volume":"186","author":"Enomoto","year":"2008","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharep.2016.04.002_bib0570","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2013.02.019","article-title":"Effects of lurasidone on executive function in common marmosets","volume":"246","author":"Murai","year":"2013","journal-title":"Behav Brain Res"},{"issue":"10","key":"10.1016\/j.pharep.2016.04.002_bib0575","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/npp.2012.64","article-title":"Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist","volume":"37","author":"Horiguchi","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0580","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/mol.111.076141","article-title":"The novel antipsychotic drug lurasidone enhances N-methyl-d-aspartate receptor-mediated synaptic responses","volume":"81","author":"Yuen","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharep.2016.04.002_bib0585","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbr.2011.01.034","volume":"220","author":"Horisawa","year":"2011","journal-title":"Behav Brain Res"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0590","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.111.180638","article-title":"The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats","volume":"338","author":"Horiguchi","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2016.04.002_bib0595","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bbr.2015.10.044","article-title":"Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition","volume":"301","author":"Miyauchi","year":"2016","journal-title":"Behav Brain Res"},{"issue":"4","key":"10.1016\/j.pharep.2016.04.002_bib0600","doi-asserted-by":"crossref","first-page":"pyu061","DOI":"10.1093\/ijnp\/pyu061","article-title":"Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex","volume":"18","author":"Luoni","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2016.04.002_bib0605","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2015.12.023","article-title":"Chronic mild stress-induced alterations of clock gene expression in rat prefrontal cortex: modulatory effects of prolonged lurasidone treatment","volume":"104","author":"Calabrese","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharep.2016.04.002_bib0610","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.neuropharm.2013.01.023","article-title":"Effects of lurasidone in behavioral models of depression role of the 5-HT(7) receptor subtype","volume":"70","author":"Cates","year":"2013","journal-title":"Neuropharmacology"},{"issue":"16","key":"10.1016\/j.pharep.2016.04.002_bib0615","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1017\/S1461145712001332","article-title":"Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats","volume":"16","author":"Luoni","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.pharep.2016.04.002_bib0620","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.euroneuro.2015.07.007","article-title":"Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain","volume":"25","author":"Stan","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0625","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145711000150","article-title":"Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress","volume":"15","author":"Fumagalli","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.pharep.2016.04.002_bib0630","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euroneuro.2013.12.010","article-title":"alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence","volume":"24","author":"Luoni","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0635","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00213-012-2900-0","article-title":"Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid","volume":"226","author":"Calabrese","year":"2013","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0640","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4088\/JCP.12m07992","article-title":"Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study","volume":"74","author":"McEvoy","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2016.04.002_bib0645","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80mg\/day and 160mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial","volume":"145","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0650","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eurpsy.2014.08.001","article-title":"Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies","volume":"30","author":"Loebel","year":"2015","journal-title":"Eur Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0655","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies","volume":"20","author":"Nasrallah","year":"2015","journal-title":"CNS Spectr"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0660","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pharep.2016.04.002_bib0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-9338(14)77840-X","article-title":"Long-term safety and effectiveness of lurasidone in schizophrenia: results of a 22 month, open-label extension study","volume":"29","author":"Correll","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0670","doi-asserted-by":"crossref","first-page":"67","DOI":"10.12740\/PP\/33909","article-title":"The place of quetiapine extended release in the treatment of mental disorders","volume":"49","author":"Stycze\u0144","year":"2015","journal-title":"Psychiatr Pol"},{"issue":"1","key":"10.1016\/j.pharep.2016.04.002_bib0675","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study","volume":"147","author":"Loebel","year":"2013","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.pharep.2016.04.002_bib0680","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4088\/JCP.12m08084","article-title":"Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study","volume":"74","author":"Stahl","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2016.04.002_bib0685","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S109285291300093X","article-title":"Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study","volume":"19","author":"Citrome","year":"2014","journal-title":"CNS Spectr"},{"key":"10.1016\/j.pharep.2016.04.002_bib0690","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.pharep.2016.04.002_bib0695","first-page":"75","article-title":"Management of bipolar I depression: clinical utility of lurasidone","volume":"11","author":"Findlay","year":"2015","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0700","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharep.2016.04.002_bib0705","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2013.10.040","article-title":"Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"155","author":"Citrome","year":"2014","journal-title":"J Affect Disord"},{"issue":"6","key":"10.1016\/j.pharep.2016.04.002_bib0710","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/acps.12343","article-title":"Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis","volume":"130","author":"Taylor","year":"2014","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0715","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.pharep.2016.04.002_bib0720","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/acps.12332","article-title":"Risk factors for suicide in schizophrenia: systematic review and clinical recommendations","volume":"130","author":"Popovic","year":"2014","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0725","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852913000904","article-title":"Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia","volume":"19","author":"Loebel","year":"2014","journal-title":"CNS Spectr"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0730","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2016.04.002_bib0735","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharep.2016.04.002_bib0740","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics","volume":"163","author":"Heres","year":"2006","journal-title":"Am J Psychiatry"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016300202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:28Z","timestamp":1752611788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2016.04.002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S1734114016300202"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2016.04.002","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2016.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}